



AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

Date:14/02/2023

To,
National Stock Exchange of India Ltd
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400051

Subject: Statement on Deviation or Variation of Funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

SYMBOL: AJOONI

Dear Sir/Madam

Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, please note that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Right Issue of the Company during the third quarter ended December 31, 2022, as mentioned in letter of offer dated November 25, 2022. Please find enclosed herewith a statement in this regard.

The aforesaid statement has been reviewed by the Audit committee and taken on record by the Board at their respective meeting held on February 14, 2023.

Kindly take the same on your record.

Thanking You,

Yours Truly,

For AJOONI BIOTECH LIMITED

7701*
Jasjot Singh
Managing Director
DIN: 01937631





AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED

Name of Listed Entity	Ajooni Biotech Limited
Mode of Fund Raising	Right Issue
Date of Raising Funds	24.12.2022 (Date of Allotment)
Amount raised	Rs. 22,55,14,866
Report filed for Quarter ended	31.12.2022
Monitoring Agency	-
Monitoring Agency Name, if applicable	-
Is there a Deviation/Variation in use of fund raised	No
If Yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unit Holders	-
If Yes, Date off Unit holders Approvals	-
Explanation for the Deviation/Variation	
Comments of the Audit Committee after review	-
Comments of the auditors, if any	

Set forth below are objects for which funds have been raised in the Right Issue and details of Deviation, if any, in the following Table:

Original Object	Modified Object, if any	Original Allocation (Rs. In lakhs)	Modified Allocation, if any	Funds utilised (Rs. In lakhs)	Amount of Deviation/Variation for Quarter according to applicable object	Remarks, if any
To part finance the requirement of Working Capital	NA	2176.62	1691.81	553.38		NA
To meet General Corporate purposes	NA	700.00	543.94	475.14		NA
To meet the	NA	25.00	19.39	26.63		NA





AJOONI BIOTECH LIMITED

Regd. Office: D-118, Industrial Area, Phase VII, Mohali-160055 (Pb.)

Phone: 0172-5020758-69 Website: www.ajoonibiotech.com

E-mail: ajooni.biotech@gmail.com / info@ajoonibiotech.com

CIN: L85190PB2010PLC040162

expenses of the Issue						
Total		2901.62	2255.15 (under subscription)	1055.1 5 (funds utilised)		

Note: Rs. 1200 lakhs is un-utilised/ Bank Balance

Deviation or Variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of Funds actually utilized as against what was originally disclosed or
- Change in terms of a contract referred to in the fund raising document i.e letter of Offer.

For AJOONI BIOTECH LIMITED

770*



Jasjot Singh
Managing Director
DIN: 01937631